Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

Adam Khorasanchi, Merve Hasanov, Richard Wu, Hisham Alsharif, Kari Kendra, Claire Verschraegen^*
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
* Corresponding Author: Claire Verschraegen. Email: email

Oncology Research https://doi.org/10.32604/or.2026.069012

Received 11 June 2025; Accepted 26 November 2025; Published online 05 February 2026

Download PDF

Abstract

Cutaneous squamous cell carcinoma (CSCC) is the second most common type of skin cancer and typically involves the head and neck. Systemic therapy is often required for patients with advanced CSCC to achieve optimal disease control. Immune checkpoint inhibitors (ICIs) are now the standard of care for these patients, with a 50%–60% response rate and sustainable remission for at least 30% of patients. Given the activity of ICIs in advanced head and neck CSCC, ICIs are being studied in early-stage disease or neoadjuvant situations. The purpose of this review is to provide an overview of the innovative perioperative strategies in resectable disease and discuss novel immunotherapeutic strategies designed to overcome treatment resistance. In conclusion, neoadjuvant ICIs have demonstrated impressive response rates with unclear survival benefit. The effectiveness of adjuvant ICIs is currently being explored. Emerging biomarkers, such as circulating tumor DNA (ctDNA), will be crucial for optimizing patient selection and improving treatment outcomes.

Keywords

Neoadjuvant; adjuvant; immunotherapy; immune checkpoint inhibitors; head and neck; cutaneous squamous cell carcinoma

Downloads
- Full-Text PDF
Citation Tools
- BibTex
- EndNote
- RIS

30

View
5

Download
0

Like

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus
YI-NONG CHEN, YING-LIN CHEN, WAN-MING...
Identification and verification of aging-related lncRNAs for prognosis prediction and immune microenvironment in patients with head and neck squamous...
QING GAO, YUJING SHI, YUANYUAN...
Thioredoxin domain-containing protein 9 protects cells against UV-B-provoked apoptosis via NF-κB/p65 activation in cutaneous squamous cell carcinoma
ZHIXUN XIAO, QIUYUN XU, HAIQING...
A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker
YANGQING HUANG, XINLAN ZHOU, XIUFEN...
Apolipoprotein C1 promotes tumor progression in gastric cancer
QIOU GU, TIAN ZHAN, XIAO GUAN,...

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

Abstract

Keywords

30

5

0

Further Information

Guidelines

Follow Us

Join Us

Contact Us

WhatsApp:

Share Link